Abstract 3779
Background
HER2-gene mutations are considered to be an important prognostic factor in patients with lung cancer. The aim of our study was to assess the frequency and significance of HER2-gene single nucleotide polymorphisms -1985G>T and P1170AC>G among the patients with small-cell and non-small cell lung cancer and to compare this data to healthy subjects.
Methods
The study was performed among 359 patients (69% males and 31% females; mean age of 59.96 ± 18.24 years) with diagnosis of stage IV small-cell (24.6% of patients) and non-small cell lung cancer (75.4% of patients) compared to 167 healthy subjects (72% males and 28% females; mean age of 69.96 ± 11.74 years). The frequencies of two polymorphisms of the HER-2-gene -1985G>T and P1170A C>G were detected using the quantitative real-time polymerase chain reaction (qRT-PCR) restriction fragment length polymorphism (RFLP) assay. The study was conducted according to the Declaration of Helsinki, the protocol was reviewed and approved by the institutional Ethics committee and all patients provided written informed consent.
Results
We found statistically significant difference in the distribution of genetic mutation variants -1985G>T and P1170A C>G among the patients with lung adenocarcinoma compared to healthy subjects (p < 0.001). The -1985G>T and P1170A C>G allelic variants were not significantly expressed among the patient and control groups in overall subject (p = 0.874).
Conclusions
Our study indicates that the expressions of genetic variants -1985G>T and P1170A C>G is associated with higher risk of development of lung adenocarcinoma. There was no statistical difference among patient and control groups in overall subjects.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2182 - Evaluating the prevalence of the expression of PD-L1 in NSCLC specimens with short-duration formalin fixation using IHC 22C3 pharmDx
Presenter: Keiichi Ota
Session: Poster Display session 1
Resources:
Abstract
5255 - [18F]-FDG PET/CT in predicting PD-L1 status in nasopharyngeal carcinoma
Presenter: Liang Zhao
Session: Poster Display session 1
Resources:
Abstract
4910 - Expression of PD-L1 in Chinese Patients with Common Cancers
Presenter: Min Zheng
Session: Poster Display session 1
Resources:
Abstract
4227 - The clearance of EGF by tumor-associated macrophages is suppressed by chemotherapeutic agent cisplatin
Presenter: Irina Larionova
Session: Poster Display session 1
Resources:
Abstract
5222 - VHIO-300 and a thousand one nights, a tale of Precision Medicine
Presenter: Ginevra Caratù
Session: Poster Display session 1
Resources:
Abstract
5668 - Matched Whole-Genome Sequencing and Whole-Exome Sequencing with Circulating Tumor DNA (ctDNA) Analysis are complementary modalities in clinical practice
Presenter: Robin Imperial
Session: Poster Display session 1
Resources:
Abstract
5772 - Exploring the role of genes associated with familial cancer syndromes on the development of multiple primary tumors
Presenter: Atanaska Mitkova
Session: Poster Display session 1
Resources:
Abstract
4784 - Doxorubicin resistance: early and advanced tumors can use two different strategies based on initial and profound abnormalities in microRNA expression signature
Presenter: Volodymyr Halytskiy
Session: Poster Display session 1
Resources:
Abstract
3456 - From tumor transcriptomes to underlying cell type proportions to better predict prognosis and response to treatments
Presenter: Yuna Blum
Session: Poster Display session 1
Resources:
Abstract
4976 - Optimization of automated germline DNA extraction from non-tumoral formalin-fixed paraffin embedded (FFPE) tissues
Presenter: Omar Youssef
Session: Poster Display session 1
Resources:
Abstract